Complete data analysis confirms that the primary endpoint of improved clinical
response and key secondary endpoints were met in a subprotocol under the
platform ACCORD2 study where bemcentinib was added to standard of care therapy
BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU
-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 patients
Bergen, Norway,April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today that a complete data analysis of a
randomized phase II study of bemcentinib in combination with standard of care
(SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19 patients confirms
that the primary efficacy endpoint was met.
At the July 2021 European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) meeting, the Company previously presented preliminary data
from the ACCORD2 study in combination with a second COVID-19 study (BGBC020)
showing evidence of therapeutic benefit on meaningful clinical endpoints in a
total of 177 patients. Today's announcement is the first time complete ACCORD2
data in a total of 61 treated patients has been separately reported.
Overall, 90% of patients treated with bemcentinib + SoC (26 of 29) experienced a
clinical response by day 29 (median 7.0 days), as defined by either a two-point
improvement in World Health Organization (WHO) category from baseline score, or
discharge from hospital, whichever arose sooner. This compared to 69% (22 of 32
patients) with a clinical response to SoC treatment alone (median 9.5 days),
showing statistical significance.
The data was generated under a sub-protocol of the platform ACCORD2 study
(ACCORD2; EudraCT 2020-001736-95 - BGBIL019), a multi-center phase II randomized
study designed to assess the efficacy and safety of candidate agents as add-on
therapies to SoC for the treatment of COVID-19 in hospitalized patients.
Overall, 98% of patients received dexamethasone or an equivalent steroid in
their SoC, and 18% received immunomodulatory treatment with tocilizumab. The
antiviral remdesivir was used in 53% of those randomized to SoC alone, and in
21% of patients treated with bemcentinib.
In addition, key secondary endpoints saw statistically significant improvements
for the bemcentinib + SoC arm compared to SoC alone, including avoidance of any
deterioration by ?1-point increase in WHO score (including death) and ventilator
-free survival over 29 days. At day 29, 97% of bemcentinib + SoC treated
patients were alive compared to 81% of SoC-alone.
Bemcentinib treatment was well tolerated in this patient population, with no
clinically relevant safety signals in comparison to standard of care treatment.
These latest results underline bemcentinib's potential in COVID-19 and other
severe respiratory infections. As previously announced, bemcentinib will be
studied in the EU-SolidAct trial in up to 500 hospitalized COVID-19 patients.
Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS, Professor of Respiratory
Medicine and Chief Investigator on the ACCORD program commented:"With COVID-19
still driving hospital admissions globally it is key that new, more effective
treatments are being developed. These results from the ACCORD2 program indicate
that bemcentinib has demonstrated real promise as a new therapeutic option for
hospitalized patients and it now warrants testing in larger studies. These
results are a testament to the great collaboration between the NHS, NIHR, the
MEU and our Southampton research teams with more exciting results to follow from
the platform."
Martin Olin, Chief Executive Officer of BerGenBio, commented:"We are highly
encouraged by the final data from our ACCORD2 study in hospitalized COVID-19
patients. The ability of bemcentinib to add a statistically significant benefit
in clinical response over standard of care therapy is promising. We look forward
to moving to the next step in the development of bemcentinib for COVID-19
through our participation in the EUSolidAct platform study, designed to enrol up
to 500 hospitalized COVID-19 patients."
Contacts:
For BerGenBio: Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com
About ACCORD2 study
Under the bemcentinib sub-protocol of the ACCORD2 study, patients were enrolled
within a calendar day after being admitted to hospital. Eligible patients were
categorized by the WHO 9-point clinical scale and ranged from patients who did
not require supplementary oxygen (grade 3) to those requiring non-invasive
ventilation or high-flow nasal oxygen, but not intubated (grade 5). In the
bemcentinib sub-protocol 29 patients were randomized and received bemcentinib
treatment in addition to SoC.
For further details: https://clinicaltrials.gov/ct2/show/NCT04890509
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.